The drugmaker, along with its partner Eisai, published an open letter to CMS about the coverage proposal Feb. 10. Under the current proposal, Medicare would only cover Aduhelm for patients in clinical trials, a move that would deny “almost all Medicare beneficiaries access to Aduhelm — the only FDA-approved treatment for Alzheimer’s disease in nearly 20 years,” Priya Singhal, MD, Biogen’s head of research and development, wrote in the letter.
The restriction would also significantly limit and delay coverage for Aduhelm and future similar drugs and create a “major burden for providers, patients and CMS,” Dr. Singhal added.
The drugmaker asked CMS to reverse its position and expand coverage of Aduhelm in accordance with its FDA-approved indications.
CMS is set to issue a final determination on Aduhelm coverage April 11.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
